Irvine, United States
Urovant Sciences, a company founded in 2017 and headquartered in the United States, is now part of Sumitomo Pharma America as of July 2023. This transition marks Urovant's integration into a larger, science-based, technology-driven biopharmaceutical ecosystem focused on delivering therapeutic breakthroughs in critical patient areas. The company's strategic objective has been to advance urologic patient care through innovation, diversity of thought, and compassionate care.
Prior to its integration, Urovant Sciences aimed to establish itself as a leading specialty company trusted by patients and providers for its commitment to tackling urologic conditions. The company previously secured a $100.00M Post Ipo Debt investment from Hercules Capital on February 1, 2019, indicating confidence in its growth potential and operational strategy. This acquisition by Sumitomo Pharma America may further bolster their development in delivering innovative therapies in underaddressed medical fields.
Astellas Pharma